Evidence map›Paper›PMID 33528622›Full record

ArticleVirchows Archiv : an international journal of pathology2021

Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Sietse M Aukema, Giorgio A Croci, Susanne Bens, Kathrin Oehl-Huber, Rabea Wagener, German Ott, Andreas Rosenwald, Philip M Kluin, Eva van den Berg, Anneke G Bosga-Bouwer and 13 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 4 countries.

Sietse M Aukema *Institute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. smaukema@gmail.com.ORCID http://orcid.org/0000-0001-5824-0320
Giorgio A Croci *Hematopathology Section, Christian-Albrechts-University, Kiel, Germany.
Susanne BensInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Kathrin Oehl-HuberInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Rabea WagenerInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, Würzburg, Germany.
Philip M KluinDepartment of Pathology & Medical Biology, University Medical Center Groningen, Groningen, the Netherlands.
Eva van den BergDepartment of Genetics, University Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Anneke G Bosga-BouwerDepartment of Genetics, University Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Mels HoogendoornDepartment of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands.
Eva HosterInstitute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität Munich, Munich, Germany.
Iris BittmannInstitute of Pathology, Agaplesion Hospital Rotenburg, Rotenburg (Wuemme), Germany.
Inga NagelInstitute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Eva M Murga PenasInstitute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Markus KreuzInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Julia BausingerInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Wilfried BelderPathologie Gütersloh, Gütersloh, Germany.
Ilske OschliesHematopathology Section, Christian-Albrechts-University, Kiel, Germany.
Martin J S DyerErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0002-5033-2236
Sandrine JayneErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK.
Reiner Siebert *Institute of Human Genetics, Christian-Albrechts University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. reiner.siebert@uni-ulm.de.
Wolfram Klapper *Hematopathology Section, Christian-Albrechts-University, Kiel, Germany. wklapper@path.uni-kiel.de.
Christian-Albrechts-Universität zu Kiel · DEUniversität Ulm · DEUniversity Medical Center Groningen · NLUniversity of Leicester · GBAgaplesion Diakonieklinikum Rotenburg · DEFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITLeipzig University · DEMedisch Centrum Leeuwarden · NLRobert Bosch Hospital · DEUniversity of Würzburg · DEZimmer Biomet (Germany) · DE

Funding

Medical Research Council MC_U132670597
6 · The paper itself

Abstract

Chromosomal breakpoints involving the MYC gene locus, frequently referred to as MYC rearrangements (MYC - R+), are a diagnostic hallmark of Burkitt lymphoma and recurrent in many other subtypes of B-cell lymphomas including follicular lymphoma, diffuse large B-cell lymphoma and other high-grade B-cell lymphomas and are associated with an aggressive clinical course. In remarkable contrast, in MCL, only few MYC - R+ cases have yet been described. In the current study, we have retrospectively analysed 16 samples (MYC - R+, n = 15, MYC - R-, n = 1) from 13 patients and describe their morphological, immunophenotypic and (molecular) genetic features and clonal evolution patterns. Thirteen out of fifteen MYC - R+ samples showed a non-classical cytology including pleomorphic (centroblastic, immunoblastic), anaplastic or blastoid. MYC translocation partners were IG-loci in 4/11 and non-IG loci in 7/11 analysed cases. The involved IG-loci included IGH in 3 cases and IGL in one case. PAX5 was the non-IG partner in 2/7 patients. The MYC - R+ MCL reported herein frequently displayed characteristics associated with an aggressive clinical course including high genomic-complexity (6/7 samples), frequent deletions involving the CDKN2A locus (7/10 samples), high Ki-67 proliferation index (12/13 samples) and frequent P53 expression (13/13 samples). Of note, in 4/14 samples, SOX11 was not or only focally expressed and 3/13 samples showed focal or diffuse TdT-positivity presenting a diagnostic challenge as these features could point to a differential diagnosis of diffuse large B-cell lymphoma and/or lymphoblastic lymphoma/leukaemia.

Indexed as

Chromosome BreakpointsGene RearrangementAgedAged, 80 and overBiomarkers, TumorChild, PreschoolClonal EvolutionComparative Genomic HybridizationCyclin D1Cytogenetic AnalysisDiagnosis, DifferentialDNA NucleotidylexotransferaseFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryBiomarkers, TumorCCND1 protein, humanCyclin D1DNA NucleotidylexotransferaseMYC protein, humanProto-Oncogene Proteins c-mycBlastoidCDKN2AClonal evolutionMantle cell lymphomaMCLMYCP53SOX11TdTTerminal deoxynucleotidyl transferaseTP53

Identifiers

PMID33528622
OpenAlexW3127654988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.